Navigation Links
Allos Therapeutics Reports Third Quarter 2007 Financial Results
Date:11/5/2007

in patients with lymphoma and non-small cell lung cancer (NSCLC).

PROPEL

In September 2007, the Company announced the completion of pre-planned interim analyses of patient response and safety data from the Company's pivotal Phase 2 PROPEL trial of PDX in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review. In addition, an independent Data Monitoring Committee (DMC) completed an interim analysis of the safety data from the first 35 evaluable patients and recommended that the trial continue per the protocol. In accordance with the trial protocol, the DMC will conduct another interim analysis of safety data from the first 65 evaluable patients. The Company expects to report the outcome of the 65-patient safety analysis by the end of 2007 and complete enrollment in the trial in the second quarter of 2008.

PDX in CTCL

In August 2007, the Company announced the initiation of patient enrollment in a Phase 1, open-label, multi-center study of PDX with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Up to 56 evaluable patients will be enrolled in the study with the objective of determining the optimal dose and safety profile of PDX in this population. A total of 20 of these patients will be enrolled at the determined optimal dose and schedule.

PDX in NSCLC (Phase 1)

In October 2007, data from the Company's Phase 1 dose ranging study of PDX with vitamin B12 and folic acid supplementation in patients with previously treated advanced NSCLC were presented at the 2007 AACR-NCI-EORTC conference. In this study, a total of 22 patients with relapsed or refractory NSCLC were treated at doses
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... 02, 2015 , ... Back packs can be dangerous? Whaaat?! , Not the ... wreck havoc on a kid's spine. With school starting again, most kids will be ... sure you are aware of how to help them prevent injuries by understanding backpack ...
(Date:8/1/2015)... ... August 01, 2015 , ... Have you ever wondered what “Karma” really means? Does it ... word “Karma.” , Vedic tradition, which gave birth to Hinduism, is one of the ... central concepts of this tradition. According to the wisdom of this heritage, Karma is a ...
(Date:8/1/2015)... ... ... Calvary Hospital today announced that it is embarking on a yearlong restoration ... bring this Torah – dating from 1880 – back to kosher status, so that ... Scroll No. 515, from the town of Taus-Domazlice, is on permanent loan to Calvary ...
(Date:8/1/2015)... ... 2015 , ... Brig and Lita Hart, icons of the network marketing industry ... Home mission with the HOPE Movement of EvolvHealth. In what has been a long-term ... agreed to join their missions of purpose together to change the course of the ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, ... who are thought to have been behind the attack on Anthem Inc. which resulted ... zero day exploits, watering hole attacks and spear phishing campaigns. , For ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4
... May 31 Telik, Inc. (Nasdaq: TELK ... of the American Society of Clinical Oncology (ASCO) in ... randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination ... second-line therapy in platinum refractory or resistant ovarian cancer. ...
... - New research quantifies the precise effects of environmental ... studies being presented this week during Digestive Disease Week ... that the environment and alcohol intake can affect GI ... future research. DDW is the largest international gathering of ...
... breast tumor treatments called ,exciting, , , SUNDAY, May 31 ... nice to be anywhere," singer and actress Olivia Newton-John, ... one of the world,s largest gatherings of cancer specialists ... news briefing on advances and insights in breast and ...
... seek alternatives to SSRIs for hot flashes, studies suggest ... antidepressants that many breast cancer survivors use to dampen ... boost the odds of the disease,s return, new research ... the American Society of Clinical Oncology,s annual meeting, in ...
... cyclists to start San Francisco-to-Los Angeles ride May 31SAN ... 2,150 bicyclists from 41 states and 14 nations will ... route to Los Angeles as participants in the colorful ... 545-mile trek is expected to raise $10.5 million to ...
... Red technology (NIR) delivers revolutionary pain free hair removal. ... UK to offer genuine groundbreaking hair removal laser technology ... 31 Transform, the UK,s largest group of plastic ... of the first in the UK to install the ...
Cached Medicine News:Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 2Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 3Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 4Health News:To what extent can environmental pollutants and alcohol affect GI health? 2Health News:To what extent can environmental pollutants and alcohol affect GI health? 3Health News:New Insights, Inroads Against Breast, Ovarian Cancers 2Health News:New Insights, Inroads Against Breast, Ovarian Cancers 3Health News:New Insights, Inroads Against Breast, Ovarian Cancers 4Health News:New Insights, Inroads Against Breast, Ovarian Cancers 5Health News:Some Antidepressants May Thwart Tamoxifen's Effect on Breast Cancer 2Health News:Some Antidepressants May Thwart Tamoxifen's Effect on Breast Cancer 3Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 3Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 4Health News:Pain-Free, Hair-Free System Set to Transform Hair Removal 2Health News:Pain-Free, Hair-Free System Set to Transform Hair Removal 3
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... Reports Significantly More Patients Treated,with Taxotere(R)-Based ... CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- ... maintained long-term efficacy as a treatment ... to the three-year updated results of ...
... - Schering-Plough Corp. announced results,from a Phase ... (pegylated liposomal doxorubicin hydrochloride),significantly prolonged time to ... with infrequent and manageable clinical,toxicity after first-line ... 43rd Annual Meeting of the American Society ...
Cached Medicine Technology:Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 2Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 3Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: